RET
12 drugsRearranged During Transfection Proto-Oncogene
Predictive biomarker for patient selection in 25 indications
Understanding RET
What it means: RET alterations include fusions (lung cancer) and point mutations (thyroid cancer). Drives cancer through constitutive kinase activity.
Why it matters: Selective RET inhibitors selpercatinib and pralsetinib show high response rates in RET-altered cancers.
Testing: Tested via NGS for fusions and mutations. FISH can detect rearrangements but misses mutations.
12
Approved Drugs
25
Indications
10
Companies
RET is a precision-medicine biomarker linked to 12 FDA-approved targeted drugs from 10 companies, spanning 25 indications including Metastatic RET fusion-positive non-small cell lung cancer, Advanced or metastatic RET fusion-positive thyroid cancer, Gastrointestinal Stromal Tumor. Explore the targeted therapies, indications, testing methods, and companies developing RET drugs below.
Search RET Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting RET
| Drug | Company | Therapeutic Area |
|---|---|---|
| ALECENSA | Roche | Oncology |
| CABOMETYX | EXELIXIS | Oncology |
| CAPRELSA | Sanofi | Oncology |
| COMETRIQ | EXELIXIS | Oncology |
| GAVRETO | RIGEL PHARMS | Oncology |
| ICLUSIG | Takeda | Oncology |
| NEXAVAR | Bayer | Oncology |
| RESNIBEN | AZURITY | Oncology |
| SORAFENIB TOSYLATE | Dr. Reddy's | Oncology |
| STIVARGA | Bayer | Oncology |
| SUNITINIB MALATE | MSN | Oncology |
| SUTENT | CPPI CV | Oncology |
RET Indications
Metastatic RET fusion-positive non-small cell lung cancer Advanced or metastatic RET fusion-positive thyroid cancer Gastrointestinal Stromal Tumor Renal Cell Carcinoma Pancreatic Neuroendocrine Tumor Hepatocellular Carcinoma Thyroid Carcinoma Medullary Thyroid Cancer Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Advanced renal cell carcinoma Hepatocellular carcinoma previously treated with sorafenib Locally advanced or metastatic differentiated thyroid cancer Well-differentiated pancreatic neuroendocrine tumors Well-differentiated extra-pancreatic neuroendocrine tumors Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma Gastrointestinal stromal tumor (GIST) Advanced renal cell carcinoma (RCC) Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomy Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) Non-Small Cell Lung Cancer Unresectable hepatocellular carcinoma Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment